- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01534143
High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant
A Pilot Study Using High Dose Busulfan and Bortezomib as Part of Allogeneic Transplant Conditioning Regimen for High Risk Multiple Myeloma Patients.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
PRIMARY OBJECTIVES:
I. To determine time to engraftment absolute neutrophil count (> 0.5 x 10^9/L for 3 consecutive days), and platelet (> 20X 109^/L for 3 consecutive days).
2. Incidence and severity of acute graft-versus-host disease (GVHD) using fludarabine (fludarabine phosphate) / busulfan / bortezomib preparative regimen and triple immune suppression with tacrolimus, sirolimus and Thymoglobulin (anti-thymocyte globulin).
3. To determine the safety related to this combination in the first six months post transplant, specifically, treatment related mortality and grade III and IV non hematologic toxicities, based on Common Terminology Criteria for Adverse Events (CTCAE) version 4 (v4).
SECONDARY OBJECTIVES:
I. Incidence of myeloma progression in this high risk group of patients.
II. Incidence of transplant related mortality and morbidity.
III. Incidence of thrombotic thrombocytopenic purpura (TTP) and sinusoidal obstructive syndrome (SOS).
IV. Incidence and severity of chronic GVHD.
V. Incidence of opportunistic infections including cytomegalovirus (CMV), herpes simplex virus (HSV), and Epstein-Barr virus (EBV) reactivation.
I. Overall and progression free survival (PFS) at Day 100, 6 months, 1 & 2 years post transplant.
VII. To determine recovery of T-cell, B cell, and natural killer (NK) cell phenotypes post transplant.
OUTLINE:
CONDITIONING REGIMEN: Patients receive fludarabine phosphate intravenously (IV) on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.
GVHD PROPHYLAXIS: Patients receive anti-thymocyte globulin IV on days -3 to -1, sirolimus orally (PO) on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic hematopoietic stem cell transplantation (HSCT) on day 0.
After completion of study treatment, patients are followed up for up to 2 years.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48201
- Barbara Ann Karmanos Cancer Institute
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Ability to provide informed consent
- Karnofsky Performance Status (KPS) >= 70
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2
- Availability of a suitable allogeneic hematopoietic stem cell donor; minimum of human leukocyte antigen (HLA) 7/8 matched related or unrelated donor
- High risk multiple myeloma with poor prognostic features based on having one or more of the following criteria:
- Progressive disease after autologous transplant. No less than 3 months post auto transplant
- Progressive or stable disease after induction chemotherapy using the most potent myeloma agents Lenalidomide and/or Bortezomib
- Patients with high risk cytogenetic abnormalities documented on conventional cytogenetics or fluorescence in situ hybridization (FISH) (hypodiploidy, t(4:14), t(14:16) chromosome translocation, p53 and or complex cytogenetics) additionally, chromosome 13 deletion by standard cytogenetics
- Negative beta-human chorionic gonadotropin (β-HCG) pregnancy test for women, as well as implementation of birth control for men and women
Exclusion Criteria:
- Patients with prior allogeneic transplant, or more than one prior autologous transplant for any medical reason
- Prior treatment with busulfan or gemtuzumab (Mylotarg ®) for any reason
- Patient with history of allergy to boron, mannitol, or bortezomib
- Creatinine clearance (CrCl) =< 50 ml/min
- Ejection Fraction < 50%
- Diffusion capacity of carbon monoxide (DLCO) < 50% predicted
- Forced expiratory volume in 1 second (FEV1) < 50% predicted
- Forced vital capacity (FVC) < 50% predicted
- Patients with uncontrolled arrhythmia or uncontrolled heart disease at the screening time; patients with coronary heart disease (recent myocardial infarctions, angina, cardiac stent, or bypass surgery in the last 6 months) need to be cleared with a stress echo or nuclear myocardial perfusion stress test, and cardiology consult; all other cardiac history will be at the discretion of the principal investigator
- Liver enzymes > 3 times upper limit normal
- Bilirubin > 2 mg/dl (except Gilbert's disease)
- International normalized ratio (INR) > 2
- Any previous history of liver failure, hepatitis, or cirrhosis
- Systemic Amyloidosis Known history of hepatitis B, C, human immunodeficiency virus (HIV) or any current uncontrolled infection
- Grade > I neuropathy
- Women who are pregnant or lactating
- Current or history of alcohol or drug abuse
- Use of other investigational agents within 30 days of enrollment to this study
- Any patient with ascites
- Any patient on home oxygen
- Any clinical findings on history or physical exam which would in the opinion of the treating physician or principal investigator preclude the patient from participating in the study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Treatment (chemotherapy, enzyme inhibitor)
CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2. GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0. |
Estudios correlativos
Dado IV
Otros nombres:
Estudios correlativos
Otros nombres:
Dado IV
Otros nombres:
Orden de compra dada
Otros nombres:
Dado IV
Otros nombres:
Dado IV
Otros nombres:
Someterse a HSCT alogénico
Dado IV
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Incidence and Severity of Acute GVHD Using Fludarabine Phosphate / Busulfan / Bortezomib Preparative Regimen and Triple Immune Suppression With Tacrolimus, Sirolimus and Anti-thymocyte Globulin
Periodo de tiempo: First 6 months post-transplant
|
Graded using the Glucksberg scale.
Proportions and confidence intervals will be estimated.
Estimated using binary proportion estimates as well as competing risk method.
|
First 6 months post-transplant
|
Time to Platelet Absolute Neutrophil Recovery (Engraftment)
Periodo de tiempo: First 6 months post-transplant
|
Estimated using Kaplan-Meier method.
|
First 6 months post-transplant
|
Treatment Related Mortality Defined as Death in Continuous or Complete Remission
Periodo de tiempo: From the date of transplant to the date of death, assessed up to 6 months post transplant
|
Based on National Cancer Institute (NCI) CTCAE version 4.
|
From the date of transplant to the date of death, assessed up to 6 months post transplant
|
Grade III and IV Non Hematologic Toxicities
Periodo de tiempo: First 6 months post transplant
|
Based on NCI CTCAE version 4.
|
First 6 months post transplant
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Sobrevivencia promedio
Periodo de tiempo: Hasta 2 años después del trasplante
|
Hasta 2 años después del trasplante
|
Incidence of Myeloma Progression
Periodo de tiempo: Time to the first observation of disease progression/relapse post transplant, assessed up to 2 years post transplant
|
Time to the first observation of disease progression/relapse post transplant, assessed up to 2 years post transplant
|
Incidence of Transplant Related Mortality and Morbidity
Periodo de tiempo: Up to 2 years post transplant
|
Up to 2 years post transplant
|
Incidence of TTP
Periodo de tiempo: Up to 2 years post transplant
|
Up to 2 years post transplant
|
Incidence of SOS
Periodo de tiempo: Up to 2 years post transplant
|
Up to 2 years post transplant
|
Incidence and Severity of Chronic GVHD
Periodo de tiempo: Up to 2 years post transplant
|
Up to 2 years post transplant
|
Incidence of Opportunistic Infections Including CMV, HSV, and EBV Reactivation
Periodo de tiempo: Weekly to day 100
|
Weekly to day 100
|
Progression Free Survival
Periodo de tiempo: From the day of transplant to progression, death, or last contact, assessed up to 2 years
|
From the day of transplant to progression, death, or last contact, assessed up to 2 years
|
Recovery of T-cell, B Cell and NK Cell Phenotypes
Periodo de tiempo: Days 30, 60, 90, and at 6 months after transplant
|
Days 30, 60, 90, and at 6 months after transplant
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Zaid Al-Kadhimi, Barbara Ann Karmanos Cancer Institute
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades cardiovasculares
- Enfermedades Vasculares
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Neoplasias
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Enfermedades hematológicas
- Trastornos hemorrágicos
- Trastornos hemostáticos
- Paraproteinemias
- Trastornos de proteínas en sangre
- Mieloma múltiple
- Neoplasias De Células Plasmáticas
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Inhibidores de enzimas
- Antimetabolitos, Antineoplásicos
- Antimetabolitos
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Agentes antineoplásicos, alquilantes
- Agentes alquilantes
- Agonistas mieloablativos
- Agentes antibacterianos
- Antibióticos, Antineoplásicos
- Agentes antifúngicos
- Inhibidores de calcineurina
- Inmunoglobulinas
- Bortezomib
- Fludarabina
- Fosfato de fludarabina
- Tacrolimus
- Sirolimus
- Busulfán
- Timoglobulina
- Suero Antilinfocito
Otros números de identificación del estudio
- 2011-151
- NCI-2012-00120 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre análisis de biomarcadores de laboratorio
-
ORIOL BESTARDTerminadoTrasplante de riñón | Infección por CMVEspaña, Bélgica
-
Vanderbilt University Medical Center4DMedicalTerminado
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)Aún no reclutandoInfecciones por VIH | Hepatitis B
-
Johns Hopkins UniversityReclutamiento
-
University of MiamiActivo, no reclutando
-
Hvidovre University HospitalElsassFondenTerminadoAcidosis metabólica del recién nacidoDinamarca
-
Rio de Janeiro State UniversityCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... y otros colaboradoresTerminadoEnfermedades cardiovasculares | Deficiencia de vitamina D | Condiciones relacionadas con la menopausiaBrasil